Fluorescence-guided surgery of retroperitoneal-implanted human fibrosarcoma in nude mice delays or eliminates tumor recurrence and increases survival compared to bright-light surgery

• Published in: PloS one 2015-02, Vol.10 (2), p.e0116865-e0116865
• Main Authors: Uehara, Fuminari, Hiroshima, Yukihiko, Miwa, Shinji, Tome, Yasunori, Yano, Shuya, Yamamoto, Mako, Matsumoto, Yasunori, Maehara, Hiroki, Tanaka, Kazuhiro, Bouvet, Michael, Kanaya, Fuminori, Hoffman, Robert M
• Format: Article
• Language: English
• Subjects: Animals; Antigens; Bone surgery; Cell Line, Tumor; Comparative analysis; Female; Fibrosarcoma; Fibrosarcoma - pathology; Fibrosarcoma - surgery; Fluorescence; Green fluorescent protein; Green Fluorescent Proteins - genetics; Green Fluorescent Proteins - metabolism; Humans; Implantation; Labeling; Laboratories; Medicine; Metastasis; Mice; Mice, Nude; Navigation systems; Neoplasm Recurrence, Local - etiology; Neoplasm Recurrence, Local - pathology; Optical Imaging - methods; Orthopedics; Pancreatic cancer; Polyethylene glycol; Proteins; Recurrence (Disease); Retroperitoneal Neoplasms - pathology; Retroperitoneal Neoplasms - surgery; Retroperitoneum; Salmonella; Salmonella Typhimurium; Surgery; Surgery, Computer-Assisted - adverse effects; Surgery, Computer-Assisted - methods; Survival; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0116865

The aim of this study is to determine if fluorescence-guided surgery (FGS) can eradicate human fibrosarcoma growing in the retroperitoneum of nude mice. One week after retroperitoneal implantation of human HT1080 fibrosarcoma cells, expressing green fluorescent protein (GFP) (HT-1080-GFP), in nude mice, bright-light surgery (BLS) was performed on all tumor-bearing mice (n = 22). After BLS, mice were randomized into 2 treatment groups; BLS-only (n = 11) or the combination of BLS + FGS (n = 11). The residual tumors remaining after BLS were resected with FGS using a hand-held portable imaging system under fluorescence navigation. The average residual tumor area after BLS + FGS was significantly smaller than after BLS-only (0.4 ± 0.4 mm(2) and 10.5 ± 2.4 mm(2), respectively; p = 0.006). Five weeks after surgery, the fluorescent-tumor areas of BLS- and BLS + FGS-treated mice were 379 ± 147 mm(2) and 11.7 ± 6.9 mm(2), respectively, indicating that FGS greatly inhibited tumor recurrence compared to BLS. The combination of BLS + FGS significantly decreased fibrosarcoma recurrence compared to BLS-only treated mice (p < 0.001). Mice treated with BLS+FGS had a significantly higher disease-free survival rate than mice treated with BLS-only at five weeks after surgery. These results suggest that combination of BLS + FGS significantly reduced the residual fibrosarcoma volume after BLS and improved disease-free survival.